Your browser doesn't support javascript.
loading
Langerhans cells: Central players in the pathophysiology of atopic dermatitis.
Pan, Yi; Hochgerner, Mathias; Cichon, Malgorzata Anna; Benezeder, Theresa; Bieber, Thomas; Wolf, Peter.
Afiliação
  • Pan Y; Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany.
  • Hochgerner M; Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.
  • Cichon MA; Greater Bay Area Institute of Precision Medicine (Guangzhou), School of Life Sciences, Fudan University, Shanghai, China.
  • Benezeder T; Institute of Science and Technology Austria (IST Austria), Klosterneuburg, Austria.
  • Bieber T; Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.
  • Wolf P; Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany.
Article em En | MEDLINE | ID: mdl-39157943
ABSTRACT
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease worldwide. AD is a highly complex disease with different subtypes. Many elements of AD pathophysiology have been described, but if/how they interact with each other or which mechanisms are important in which patients is still unclear. Langerhans cells (LCs) are antigen-presenting cells (APCs) in the epidermis. Depending on the context, they can act either pro- or anti-inflammatory. Many different studies have investigated LCs in the context of AD and found them to be connected to all major mechanisms of AD pathophysiology. As APCs, LCs recruit other immune cells and shape the immune response, especially adaptive immunity via polarization of T cells. As sentinel cells, LCs are primary sensors of the skin microbiome and are important for the decision of immunity versus tolerance. LCs are also involved with the integrity of the skin barrier by influencing tight junctions. Finally, LCs are important cells in the neuro-immune crosstalk in the skin. In this review, we provide an overview about the many different roles of LCs in AD. Understanding LCs might bring us closer to a more complete understanding of this highly complex disease. Potentially, modulating LCs might offer new options for targeted therapies for AD patients.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article